HikalQ1 FY25

Hikal Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹217.94P/E: 37.8Market Cap: ₹2.7K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • Hikal Limited expects 10%-15% CAGR growth over the next 2-3 years starting next fiscal year, driven by ramp-up in new molecules and normalization in crop protection demand (Page 13).
  • Pharma business anticipates good volume growth due to capacity expansions and robust product pipeline, with 2-3 new product launches annually (Page 5).
  • Crop protection business faces short-term challenges but expects market improvement by Q3/Q4 FY25, supporting mid to long-term growth (Pages 4, 7).
  • CDMO segment is seeing increased customer inquiries and opportunities, with projects expected to reach peak potential within 2 years (Pages 9, 10).
  • Animal health business is in validation phase, expecting revenues to start accruing around 14-16 months post-validation, indicating growth potential over next 5 years (Page 10).
  • Overall, the company aims to double revenue over 3-4 years from FY23 base of Rs. 2000 crores through diversification and new business streams (Page 11).

See what Hikal management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • There is no specific mention of any current or immediate new fundraising through debt or equity in the call.
  • The company mentioned having a debt of Rs. 759 crores in Q1 FY25, reduced from Rs. 804 crores last quarter (a Rs. 45 crore reduction).
  • They plan to optimize CAPEX and improve debt-equity ratios starting next year, with a focus on continuous debt reduction.
  • Interest costs have increased due to capitalization of assets; these costs are expected to be absorbed over time as production ramps up.
  • CAPEX for the current year is guided to be around Rs. 120 to Rs. 140 crores, mainly for debottlenecking and maintenance, with no major significant CAPEX planned.
  • No explicit plans for raising funds via equity or debt were disclosed during the call.

See what Hikal management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Current CAPEX guidance for FY25 is approximately Rs. 120 to Rs. 140 crores, primarily focused on debottlenecking and maintenance, with no major significant new CAPEX planned currently.
  • Recent CAPEX of Rs. 600 to Rs. 800 crores has been done over the last three years, achieving 1.3x to 1.5x asset turnover.
  • Capitalization of new assets in the last 12 months has increased depreciation and interest costs, expected to be absorbed as production and sales ramp up.
  • Future CAPEX is planned for expansion in Crop Protection, Animal Health, and Pharma divisions, with validation activities ongoing, and regulatory filings expected to significantly contribute to growth.
  • No specific large-scale strategic investments announced, but focus remains on capacity expansion, cost efficiencies, and operational optimization to support 10-15% growth from FY26 onwards.

Track Hikal — get its next earnings analysis in your feed

How does Hikal rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisHikal
Rev 3Mar 3

How does Hikal rank in Pharmaceuticals & Biotechnology?

Compare Hikal against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →